Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mindy I Davis

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Medicinal Chemistry|March 3, 2012
Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic indexGang Liu, Sunny Abraham, Lan Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2019
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing SarcomaSarah Wang, Elizabeth E Hwang, Rajarshi Guha, et al.
Journal of Medicinal Chemistry|September 16, 2025
SAR Studies around the SULT1A1-Activated Alkylator YC-1 as Cytotoxic Agents against Biliary Tract Cancer CellsKe Kong, Wei Zhao, Jonathan H Shrimp, et al.
Cancer Cell|December 12, 2018
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer RemodelingAmanda Balboni Iniguez, Gabriela Alexe, Emily Jue Wang, et al.
Nature Biotechnology|January 10, 2008
A quantitative analysis of kinase inhibitor selectivityMazen W Karaman, Sanna Herrgard, Daniel K Treiber, et al.
Scientific Reports|October 8, 2017
Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assaysDaniel J Urban, Natalia J Martinez, Mindy I Davis, et al.
The Journal of Infectious Diseases|September 5, 2023
Report of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug DevelopmentRobert Jordan, Stephanie L Ford-Scheimer, Rodolfo M Alarcon, et al.
Journal of Medicinal Chemistry|April 6, 2021
Discovery and Optimization of 2<i>H</i>-1λ<sup>2</sup>-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of CancerJason M Rohde, Surendra Karavadhi, Rajan Pragani, et al.
Nature Cancer|March 14, 2023
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancersLei Shi, William Shen, Mindy I Davis, et al.
The Journal of Infectious Diseases|June 10, 2021
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics SummitMatthew D Hall, James M Anderson, Annaliesa Anderson, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Medicinal Chemistry|March 3, 2012
Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic indexGang Liu, Sunny Abraham, Lan Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2019
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing SarcomaSarah Wang, Elizabeth E Hwang, Rajarshi Guha, et al.
Journal of Medicinal Chemistry|September 16, 2025
SAR Studies around the SULT1A1-Activated Alkylator YC-1 as Cytotoxic Agents against Biliary Tract Cancer CellsKe Kong, Wei Zhao, Jonathan H Shrimp, et al.
Cancer Cell|December 12, 2018
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer RemodelingAmanda Balboni Iniguez, Gabriela Alexe, Emily Jue Wang, et al.
Nature Biotechnology|January 10, 2008
A quantitative analysis of kinase inhibitor selectivityMazen W Karaman, Sanna Herrgard, Daniel K Treiber, et al.
Scientific Reports|October 8, 2017
Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assaysDaniel J Urban, Natalia J Martinez, Mindy I Davis, et al.
The Journal of Infectious Diseases|September 5, 2023
Report of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug DevelopmentRobert Jordan, Stephanie L Ford-Scheimer, Rodolfo M Alarcon, et al.
Journal of Medicinal Chemistry|April 6, 2021
Discovery and Optimization of 2<i>H</i>-1λ<sup>2</sup>-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of CancerJason M Rohde, Surendra Karavadhi, Rajan Pragani, et al.
Nature Cancer|March 14, 2023
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancersLei Shi, William Shen, Mindy I Davis, et al.
The Journal of Infectious Diseases|June 10, 2021
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics SummitMatthew D Hall, James M Anderson, Annaliesa Anderson, et al.
Pageof 4